Mexidol Forte 250,250 mg 40 pcs

Mexidol^® Forte 250 is an inhibitor of free radical processes, membranoprotector with antihypoxic, stress-protective, nootropic, antiepileptic and anxiolytic action. It belongs to the class of 3-oxypyridines.

The mechanism of action of the drug Mexidol ^® Forte 250 is due to its antioxidant, antihypoxant and membrane-protective action. The drug inhibits lipid peroxidation, increases superoxide dismutase activity, increases lipid-protein ratio, improves cell membrane structure and function. Mexidol^® Forte 250 modulates the activity of membrane-bound enzymes (calcium-independent phosphodiesterase, adenylate cyclase, acetylcholinesterase), receptor complexes (benzodiazepine, GABA, acetylcholine) that increase their ability to bind to ligands, maintain the structural and functional organization of biomembranes, transport neurotransmitters and improve synaptic transmission. Mexidol^® Forte 250 increases dopamine content in the brain. Increases compensatory activation of aerobic glycolysis and decreases the degree of inhibition of oxidative processes in the Krebs cycle in hypoxia with increase of ATP and creatine phosphate, activation of energy-synthesizing functions of mitochondria.

Enhances resistance of the body to various damaging factors in pathological conditions (hypoxia and ischemia, impaired cerebral circulation, intoxication with ethanol and antipsychotic drugs).

In conditions of critical reduction of coronary blood flow promotes the preservation of structural and functional organization of cardiomyocyte membranes, stimulates the activity of membrane enzymes – phosphodiesterase, adenylate cyclase, acetylcholinesterase. It supports activation of aerobic glycolysis developing in acute ischemia and promotes under hypoxia restoration of mitochondrial redox processes, increases ATP and creatine phosphate synthesis. Ensures the integrity of morphological structures and physiological functions of ischemic myocardium. Improves the clinical course of myocardial infarction, increases the effectiveness of therapy, reduces the incidence of arrhythmias and intracardiac conduction abnormalities. Normalizes metabolic processes in ischemic myocardium, increases antianginal activity of nitrates, improves rheological properties of blood, reduces consequences of reperfusion syndrome in acute coronary failure.

Limits enzymatic toxemia and endogenous intoxication in acute pancreatitis.

It improves metabolism and blood supply of the brain, improves microcirculation and rheological properties of the blood, reduces platelet aggregation. It stabilizes membrane structures of blood cells (erythrocytes and platelets), reducing the likelihood of hemolysis. It has hypolipidemic effect, reduces the content of total cholesterol and LDL.

The anti-stressor effect is shown in normalization of post-stress behavior, somatovegetative disorders, restoration of sleep-wake cycles, disturbed learning and memory processes, decrease of dystrophic and morphological changes in different structures of the brain.

Mexidol ^® Forte 250 has a marked anti-toxic effect in withdrawal syndrome. It eliminates neurological and neurotoxic symptoms of acute alcohol intoxication, restores behavioral disorders, vegetative functions and is also able to relieve cognitive disorders caused by prolonged use of ethanol and its withdrawal. Under the influence of the drug the effect of tranquilizing drugs, neuroleptics, antidepressants, hypnotics and anticonvulsants increases, which allows reducing their doses and side effects.

The Mexidol^® Forte 250 improves the functional state of the ischemic myocardium. In conditions of coronary insufficiency it increases collateral blood supply to the ischemic myocardium, helps to preserve the integrity of cardiomyocytes and maintain their functional activity. Effectively restores myocardial contractility in reversible cardiac dysfunction.

Indications

Atherosclerosis, Hangover, Concussion and other brain injuries, Stenocardia, Headache, Exposure to adverse factors, Dizziness, Anxiety, Stroke effects, Vascular disorders, Neurosis, Impaired cerebral circulation, Asthenia, Weakness and fatigue

• sequences of acute cerebral circulation disorders, including. After transient ischemic attacks, in the phase of subcompensation (as a prophylactic course);
• light traumatic brain injury, consequences of traumatic brain injury;
• encephalopathies of various genesis (discirculatory, dysmetabolic, post-traumatic, mixed);
• dietary dystonia syndrome;
• mild cognitive disorders of atherosclerotic genesis;
• anxiety disorders in neurotic and neurosis-like states;

.

• IBS (as part of complex therapy);
• accomplishment of withdrawal syndrome in alcoholism with predominance of neurotic and vegetative vascular disorders, postabstinence disorders;
• Absolvation syndrome in alcoholismconditions after acute intoxication with antipsychotic agents;
• asthenic conditions and for the prevention of the development of somatic diseases under the influence of extreme factors and loads;
• impact of extreme (stress) factors.

.

Active ingredient

Ethylmethylhydroxypyridine succinate

How to take, the dosage

Ingestion: 250 mg 3 times daily.

The initial dose is 250 mg (1 tablet) 1-2 times daily with gradual increase until therapeutic effect; maximum daily dose is 750 mg (3 tablets).

The duration of treatment is 2-6 weeks; to relieve alcohol withdrawal – 5-7 days. Duration of the course of therapy in patients with coronary artery disease at least 1.5-2 months.

Repeated courses (as recommended by the doctor), it is desirable to carry out in the spring and autumn periods.

Interaction

Mexidol^® Forte 250 is combined with all drugs used for the treatment of somatic diseases.

It enhances the effect of benzodiazepines, antidepressants, anxiolytics, anti-Parkinsonian (levodopa) and antiepileptic drugs (carbamazepine), nitrates.

Limits the toxic effects of ethanol.

Special Instructions

Impact on driving and operating machinery

When taking the drug, caution should be exercised when working requiring rapid psychophysical reactions (driving vehicles, operating machinery, etc.).

Features

Absorption and distribution

It is rapidly absorbed when administered orally. C_max at doses of 400-500 mg is 3.5-4.0 µg/ml.

It is rapidly distributed in organs and tissues. The average retention time of the drug in the body when administered orally is 4.9-5.2 h.

Metabolism

Metabolized in the liver by glucuron conjugation. Five metabolites were identified: 3-oxypyridine phosphate is formed in liver and with the help of alkaline phosphoric acid is broken down into phosphoric acid and 3-oxypyridine; the 2nd metabolite – pharmacologically active, is formed in large amounts and is found in urine 1-2 days after administration; the 3rd is excreted in large amounts with urine; the 4th and 5th are glucuronconjugates.

Excretion

T_1/2 when administered orally is 2-2.6 hours. It is rapidly excreted with urine mainly as metabolites and in insignificant amount – unchanged. It is most intensively excreted during the first 4 hours after drug administration. Indexes of urinary excretion of unchanged drug and metabolites have individual variability.

Contraindications

• acute liver and kidney function disorders
• high individual sensitivity to the drug.

Because of insufficient study of the drug action – childhood age, pregnancy, breast-feeding.

Side effects

Individual adverse reactions of dyspeptic nature and allergic reactions are possible.

.

Overdose

Symptoms: drowsiness, insomnia.

Treatment: due to low toxicity, overdose is unlikely. Treatment is usually not required; symptoms disappear on their own within 24 hours. If symptoms are significant, supportive and symptomatic treatment is administered.

Similarities

Mexifin, Mexiprim, Neurox, Medomexi, Mexicor, Evrin, MetucinVel, Neuromexol